Protein kinase c delta expression in primary central nervous system lymphomas
Tóm tắt
Primary central nervous system lymphoma (PCNSL) is a highly aggressive non-Hodgkin lymphoma confined to the central nervous system. Diffuse large B cell lymphoma (DLBCL) is the most common subtype, and it follows a much more aggressive course than its systemic counterpart. Differential diagnosis of PCNSL and systemic DLBCL depends on clinical staging, which is expensive and time consuming. Protein kinase C delta (PKCD) is a protein with proapopitotic properties and has a major role in negative selection of B cells in germinal centers, a regulatory function in B cell receptor (BCR) pathway and MHC II expression. Mutations identified in its gene are reported to be unique for PCNSL and not encountered in systemic DLBCL. Our aim is to evaluate immunohistochemical (IHC) expression and the mutation status of PKCD in PCNSLs and systemic DLBCLs in order to find out whether PKCD could be a novel marker that could be used in differential diagnosis of both entities. A total of 43 cases diagnosed with PCNSL, and 43 cases diagnosed with systemic DLBCL were included in the study. Immunohistochemistry for PKCD antibody and Sanger sequencing targeting exon 16 and exon 18 of PKCD gene were performed. Although immunoreactivity for PKCD was observed in all PCNSL and 95.3% of systemic DLBCL cases, strong and diffuse staining was found to be more frequent in PCNSL than systemic diffuse large B cell lymphomas (p < 0.001). However, mutations defined in literature were not encountered in our cohort. While clinical staging is still the primary way for differential diagnosis of PCNSL and systemic DLBCL, the diffuse and strong PKCD expression can be used as a supportive feature for PCNSL diagnosis.
Tài liệu tham khảo
Cai Q, Fang Y, Young KH (2019) Primary central nervous system lymphoma: molecular pathogenesis and advances in treatment. Transl Oncol 12:523–538. https://doi.org/10.1016/j.tranon.2018.11.011
Deckert M, Montesinos-Rongen M, Brunn A, Siebert R (2014) Systems biology of primary CNS lymphoma: from genetic aberrations to modeling in mice. Acta Neuropathol 127:175–188. https://doi.org/10.1007/s00401-013-1202-x
Bruno A, Boisselier B, Labreche K, Marie Y, Polivka M, Jouvet A, Adam C, Figarella-Branger D, Miquel C, Eimer S, Houillier C, Soussain C, Mokhtari K, Daveau R, Hoang-Xuan K (2014) Mutational analysis of primary central nervous system lymphoma. Oncotarget 5:5065–5075. https://doi.org/10.18632/oncotarget.2080
Braggio E, Van Wier S, Ojha J, McPhail E, Asmann YW, Egan J, da Silva JA, Schiff D, Lopes MB, Decker PA, Valdez R, Tibes R, Eckloff B, Witzig TE, Stewart AK, Fonseca R, O’Neill BP (2015) Genome-wide analysis uncovers novel recurrent alterations in primary central nervous system lymphomas. Clin Cancer Res 21:3986–3994. https://doi.org/10.1158/1078-0432.CCR-14-2116
Mellor H, Parker PJ (1998) The extended protein kinase C superfamily. Biochem J 332(Pt 2):281–292. https://doi.org/10.1042/bj3320281
Limnander A, Zikherman J, Lau T, Leitges M, Weiss A, Roose JP (2014) Protein kinase Cδ promotes transitional B cell-negative selection and limits proximal B cell receptor signaling to enforce tolerance. Mol Cell Biol 34:1474–1485. https://doi.org/10.1128/MCB.01699-13
Kwon MJ, Soh JW, Chang CH (2006) Protein kinase C delta is essential to maintain CIITA gene expression in B cells. J Immunol 177:950–956. https://doi.org/10.4049/jimmunol.177.2.950
Kwon MJ, Yao Y, Walter MJ, Holtzman MJ, Chang CH (2007) Role of PKCdelta in IFN-gamma-inducible CIITA gene expression. Mol Immunol 44:2841–2849. https://doi.org/10.1016/j.molimm.2007.01.035
Shingleton JR, Dave SS (2018) Genetic convergence of rare lymphomas. Curr Opin Hematol 25:307–314. https://doi.org/10.1097/MOH.0000000000000435
Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275–282. https://doi.org/10.1182/blood-2003-05-1545
Rubenstein JL (2017) Biology of CNS lymphoma and the potential of novel agents. Hematology Am Soc Hematol Educ Program 2017:556–564. https://doi.org/10.1182/asheducation-2017.1.556
Sugita Y, Muta H, Ohshima K, Morioka M, Tsukamoto Y, Takahashi H, Kakita A (2016) Primary central nervous system lymphomas and related diseases: pathological characteristics and discussion of the differential diagnosis. Neuropathology 36:313–324. https://doi.org/10.1111/neup.12276
Phillips EH, Fox CP, Cwynarski K (2014) Primary CNS lymphoma. Curr Hematol Malig Rep 9:243–253. https://doi.org/10.1007/s11899-014-0217-2
Provencher S, Ferlay C, Alaoui-Slimani K, Devidas A, Lepretre S, de Prijck B, Sebban C, de la Fouchardiere A, Chassagne-Clement C, Ketterer N, Thyss A, Delannoy A, Tilly H, Biron P, Blay JY, Ghesquières H (2011) Clinical characteristics and outcome of isolated extracerebral relapses of primary central nervous system lymphoma: a case series. Hematol Oncol 29:10–16. https://doi.org/10.1002/hon.944
Batchelor T, Loeffler JS (2006) Primary CNS lymphoma. J Clin Oncol 24:1281–1288. https://doi.org/10.1200/JCO.2005.04.8819
Scott BJ, Douglas VC, Tihan T, Rubenstein JL, Josephson SA (2013) A systematic approach to the diagnosis of suspected central nervous system lymphoma. JAMA Neurol 70:311–319. https://doi.org/10.1001/jamaneurol.2013.606
Montesinos-Rongen M, Schmitz R, Brunn A, Gesk S, Richter J, Hong K, Wiestler OD, Siebert R, Küppers R, Deckert M (2010) Mutations of CARD11 but not TNFAIP3 may activate the NF-kappaB pathway in primary CNS lymphoma. Acta Neuropathol 120:529–535. https://doi.org/10.1007/s00401-010-0709-7
Montesinos-Rongen M, Schäfer E, Siebert R, Deckert M (2012) Genes regulating the B cell receptor pathway are recurrently mutated in primary central nervous system lymphoma. Acta Neuropathol 124:905–906. https://doi.org/10.1007/s00401-012-1064-7
Luo W, Weisel F, Shlomchik MJ (2018) B cell receptor and CD40 signaling are rewired for synergistic induction of the c-Myc transcription factor in germinal center B cells. Immunity 48:313-326.e5. https://doi.org/10.1016/j.immuni.2018.01.008